[Click e-Stock] "Samsung Biologics' Plants 1-4 at Full Capacity... Target Price Maintained"
2027 Operating Profit Forecast at KRW 2.6203 Trillion
Plant 5 Earnings to Ramp Up in 2028
“Buy” Rating and KRW 1.95 Million Target Price Maintained
Analysts say Samsung Biologics’ earnings growth will slow in 2027, but the company could post results that exceed market expectations if commercial production at Plant 5 coincides with its acquisition of PPGN, a peptide contract manufacturing company.
Plant 5 to Begin Commercial Production in Second Half of 2027... Utilization Forecast at 16%
According to Korea Investment & Securities on November 18, researcher Wi Haeju maintained a “Buy” rating and a target price of KRW 1.95 million for Samsung Biologics on November 17. With Plants 1 through 4 already operating at full capacity in 2026, the company’s earnings growth in 2027 will depend on Plant 5’s utilization rate and the consolidation of PPGN, the peptide contract manufacturing company, analysts said.
Revenue in 2027 is forecast to reach KRW 6.3297 trillion, with operating profit of KRW 2.6203 trillion. That would represent increases of 14% and 11%, respectively, from this year’s estimates. The operating margin is forecast at 41%.
With Plants 1 through 4 reaching full capacity in 2026, there is less room to increase output at the existing plants. The U.S. plant, whose utilization rate remains at around 50%, is expected to continue operating at around break-even in 2027.
Plant 5 is expected to begin producing commercial products in the second half of 2027. Korea Investment & Securities assumes a utilization rate of 16% and revenue of KRW 289 billion for Plant 5 in 2027. Researcher Wi said, “Earnings growth from the ramp-up of Plant 5 is expected to become fully evident in 2028.”
PPGN Consolidation Could Lift 2027 Revenue to KRW 7.2 Trillion... Labor Dispute a Wild Card
Korea Investment & Securities expects Samsung Biologics to complete its rights offering and the acquisition of PPGN by the end of 2026. If PPGN’s results are consolidated, revenue in 2027 is estimated to rise to KRW 7.2 trillion and operating profit to KRW 2.7 trillion. Compared with the existing forecast, the revenue growth rate would be 15 percentage points higher and the operating profit growth rate 4.3 percentage points higher.
Last year, 57% of PPGN’s revenue came from producing peptides for the treatment of metabolic diseases. Of its 37 metabolic disease projects, seven are in Phase 3 clinical trials. Korea Investment & Securities said PPGN could continue manufacturing treatments that succeed in clinical trials once they are commercialized. It added that PPGN’s standalone operating margin could rise to 20% in 2028 if orders for treatments in late-stage clinical trials or at the commercialization stage increase and operating efficiency improves.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Prolonged labor disputes and delayed orders are potential risks. As pharmaceutical contract manufacturing clients assess supply chain stability and labor relations when signing contracts, whether the company reaches an agreement with its workers could affect new orders, the report said. Researcher Wi added, “Commercial production at Plant 5 and the consolidation of PPGN could enable Samsung Biologics to post results that exceed market expectations,” but said, “We need to see signs of progress, such as a resolution to the labor dispute and large-scale orders.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.